Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Est. Listeners
Based on iTunes & Spotify (publisher stats).
- Per-Episode Audience
Est. listeners per new episode within ~30 days
25,001 - 50,000 - Monthly Reach
Unique listeners across all episodes (30 days)
25,001 - 75,000 - Active Followers
Loyal subscribers who consistently listen
15,001 - 40,000
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
On the show
From 11 epsHosts
Recent guests
Recent episodes
199. Back to Basics - Metastatic Colorectal Cancer - last line options
May 3, 2026
23m 41s
198. Back to Basics - Early Oesophageal Cancer
Apr 26, 2026
27m 38s
197. Back to Basics - Metastatic Colorectal Cancer - HER2 positive disease and PI3K mutations
Apr 18, 2026
39m 04s
196. Back to Basics - Metastatic Colorectal Cancer - BRAFV600E and KRAS
Apr 9, 2026
26m 36s
195. Back to Basics - Immunotherapy in Metastatic Colorectal Cancer
Mar 28, 2026
25m 50s
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 5/3/26 |  199. Back to Basics - Metastatic Colorectal Cancer - last line options✨ | metastatic colorectal cancertherapeutic options+5 | — | trifluridine-tipiracilLonsurf+2 | — | metastatic colorectal cancertrifluridine-tipiracil+6 | Pfizer | 23m 41s | |
| 4/26/26 | 198. Back to Basics - Early Oesophageal Cancer✨ | oesophageal cancerchemotherapy+3 | — | ESOPECCheckmate 577 | — | oesophageal cancerchemotherapy+5 | Pfizer | 27m 38s | |
| 4/18/26 | 197. Back to Basics - Metastatic Colorectal Cancer - HER2 positive disease and PI3K mutations✨ | Metastatic Colorectal CancerHER2 positive disease+4 | — | trastruzumab deruxtecan | — | metastatic colorectal cancerHER2+5 | Pfizer | 39m 04s | |
| 4/9/26 | 196. Back to Basics - Metastatic Colorectal Cancer - BRAFV600E and KRAS✨ | metastatic colorectal cancerBRAF mutations+4 | — | — | — | metastatic colorectal cancerBRAF mutations+6 | Pfizer | 26m 36s | |
| 3/28/26 | 195. Back to Basics - Immunotherapy in Metastatic Colorectal Cancer✨ | immunotherapymetastatic colorectal cancer+3 | — | pembrolizumabipilimumab+1 | — | colorectal cancerimmunotherapy+6 | Pfizer | 25m 50s | |
| 3/21/26 | 194. Back to Basics - Metastatic Colorectal Cancer✨ | metastatic colorectal cancerchemotherapy+4 | — | cetuximabpanitumumab | — | metastatic colorectal cancerchemotherapy+6 | Pfizer | 26m 41s | |
| 3/14/26 |  193. Genitourinary Cancers and Prof Jonathan E Rosenberg MD✨ | genitourinary cancersmetastatic urothelial cancer+3 | Jonathan E. Rosenberg, MD | Memorial Sloan Kettering Cancer CentreWeill Cornell Medical College | — | urothelial cancerbladder cancer+3 | Pfizer | 37m 00s | |
| 3/7/26 | 192. Back to Basics - Early Colorectal Cancer - Part 2!✨ | colorectal cancerCTDNA+4 | — | ipilimumabnivolumab | — | colorectal cancerCTDNA+5 | Pfizer | 23m 30s | |
| 2/28/26 | 191. Back to Basics - Early Colorectal Cancer✨ | colorectal canceradjuvant regimen+3 | — | IDEASTransMET+1 | — | colorectal cancerFOLFOX+6 | Pfizer | 25m 48s | |
| 2/21/26 | 190. Back to Basics - Mesothelioma✨ | mesotheliomatreatment options+3 | — | MAPSCheckmate 743 | — | mesotheliomaipilimumab+5 | Pfizer | 18m 42s | |
| 2/16/26 | 189. Back to Basics - Extensive Stage Small Cell Lung Cancer✨ | extensive stage small cell lung cancernew treatments+3 | — | tarlatamablurbinectedin+2 | — | small cell lung cancertarlatamab+6 | Pfizer | 21m 18s |
Showing 11 of 11
Sponsor Intelligence
Sign in to see which brands sponsor this podcast, their ad offers, and promo codes.
Chart Positions
4 placements across 4 markets.
Chart Positions
4 placements across 4 markets.